Adjunctive ketamine for sedation in critically ill mechanically ventilated patients: an active-controlled, pilot, feasibility clinical trial.
Marwa AmerKhalid MaghrabiMohammed BawazeerKamel AlshaikhMohammad ShabanMuhammad RizwanRashid AminEdward De VolMawadah BaaliMalak AltewerkiMehreen BanoFawziah AlkhaldiSanaa AlenaziMohammed HijaziPublished in: Journal of intensive care (2021)
Ketamine as an adjunct analgosedative agent appeared to be feasible and safe with no negative impact on outcomes, including hemodynamics. This pilot RCT identified areas of improvement in study protocol before conducting a large, adequately powered, multicenter RCT which is likely justified to investigate ketamine association with patient-centered outcomes further. Trial registration ClinicalTrials.gov: NCT04075006. Registered on 30 August 2019. Current controlled trials: ISRCTN14730035. Registered on 3 February 2020.
Keyphrases
- study protocol
- clinical trial
- randomized controlled trial
- pain management
- end stage renal disease
- double blind
- open label
- phase ii
- newly diagnosed
- intensive care unit
- phase iii
- peritoneal dialysis
- prognostic factors
- acute respiratory distress syndrome
- chronic pain
- type diabetes
- placebo controlled
- skeletal muscle
- weight loss